The drug is the generic equivalent of Supernus Pharmaceuticals’ Oxtellar XR and is used to treat partial-onset seizures in patients aged six and above. On Friday (June 6), shares of Lupin Ltd ended at ₹1,994.00, down by ₹1.30, or 0.065%, on the BSE.
The drug is the generic equivalent of Supernus Pharmaceuticals’ Oxtellar XR and is used to treat partial-onset seizures in patients aged six and above. On Friday (June 6), shares of Lupin Ltd ended at ₹1,994.00, down by ₹1.30, or 0.065%, on the BSE.